Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock News

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.26  +0.16 (+14.55%)

After market: 1.26 0 (0%)

PYXS Latest News, Press Relases and Analysis

News Image
8 days ago - Pyxis Oncology

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential...

News Image
11 days ago - Zacks Investment Research

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

Mentions: ESPR HRTX AUPH PSTV

News Image
a month ago - Pyxis Oncology

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for...

News Image
9 months ago - BusinessInsider

PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pyxis Oncology (NASDAQ:PYXS) just reported results for the second quarter of 20...

News Image
9 months ago - InvestorPlace

PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024

PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024.

News Image
a month ago - Pyxis Oncology

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with...

News Image
2 months ago - Pyxis Oncology

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a...

News Image
2 months ago - Pyxis Oncology

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has...

News Image
2 months ago - Pyxis Oncology

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody

News Image
3 months ago - Pyxis Oncology

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA®...

News Image
4 months ago - Benzinga

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges.

News Image
5 months ago - Pyxis Oncology

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where...

News Image
5 months ago - Pyxis Oncology

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC...

News Image
6 months ago - Pyxis Oncology

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York...

News Image
6 months ago - Pyxis Oncology

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation...

News Image
7 months ago - Levi & Korsinsky, LLP

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of...

News Image
8 months ago - Pyxis Oncology

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation...

News Image
9 months ago - Pyxis Oncology

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of...

News Image
9 months ago - Pyxis Oncology

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation...

News Image
10 months ago - Pyxis Oncology

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation...